AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01129440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass Ionomer Sealant
Description: Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.~After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar.
Study NCT02119455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Device
Description: Subjects receiving the OrthoAccel Aura device will be instructed to use the device for 20 minutes/day per the manufacturer's instructions during the study period.
Study NCT01919866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transplantation of CD3/CD19 depleted stem cells
Study NCT02184949 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Study NCT02184949 — intervention group
Intervention type: PROCEDURE
Intervention: Primary Percutaneous Coronary Intervention
Study NCT06215781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fully digital workflow of prosthetic fixed dental crown
Description: The intervention that was administered was a full digital workflow. It includes an initial digital planning, an optical impression with intraoral scanner and a CAD-CAM milled zirconia crown. No analog materials were used.
Study NCT00812383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Description: Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
Study NCT00812383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Description: Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
Study NCT01278134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg bid orally, up to 24 weeks
Study NCT05399940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum PSA,Delta Neutrophil Index(DNI),WBC
Description: Urine culture, prostate volume
Study NCT01267565 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dosage of amylase
Description: 4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
Study NCT06215781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined digital and conventional workflows of prosthetic fixed dental crown
Description: The intervention that was administered was a combined digital and traditional workflow. The initial planning was digital, then the impression was performed with analog impression material (silicones) and the final zirconia crown was CAD-CAM milled, with a digital procedure.
Study NCT01278134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg bid orally, up to 24 weeks
Study NCT06215781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fully conventional workflow of prosthetic fixed dental crown
Description: The intervention that was administered was a conventional workflow that doesn't provide any digital step. The impression was taken with analog material (silicones) and the final prosthesis was a metal-ceramic crown, realized on plaster cast.
Study NCT00645775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: IGOB131
Description: Comparison of 250 mg per day of Irvingia gabonensis to placebo
Study NCT03685019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Valgus Stress
Description: Valgus stress radiograph
Study NCT03685019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Varus stress
Description: Varus stress radiograph
Study NCT01278134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 24 weeks
Study NCT01278134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
Study NCT03685019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 0 degree flexion radiograph
Description: 0 degree flexion radiograph
Study NCT01278134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg bid orally, up to 24 weeks
Study NCT03208023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RESIPI Management Strategy
Description: a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).
Study NCT03208023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention
Study NCT00700921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: 40mg po once daily
Study NCT00700921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, once daily
Study NCT03223974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel DCB
Description: Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for >30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
Study NCT03223974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DES
Description: MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
Study NCT04474743 — intervention group
Intervention type: OTHER
Intervention: No intervention - cross-sectional observational only
Description: No intervention - cross-sectional observational only
Study NCT03493048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 130 mg/m²
Study NCT03493048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab, iv, 500mg/m2
Study NCT04523571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection
Study NCT03474731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Program (DSMP)
Description: The the Diabetes Self Management Program (DSMP) in a group setting: participants will attend a six week, evidence-based diabetes home self-management program. The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization.
Study NCT03474731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Patient Navigation (PN) only
Description: Tailored Patient Navigation (PN) only: trained Community Health Workers (CHW) will meet one-on-one with participants to assess the barriers experienced in adhering to medical appointments and will implement a navigation program accordingly.~The goal of this arm of the project is to try to get participants to attend recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs.
Study NCT03474731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSMP AND Tailored Patient Navigation
Description: DSMP AND Tailored Patient Navigation : patient navigation followed by 6 weeks of DSMP classes after the 3 month post-test interview.
Study NCT03474731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Self-Management Program (DSMP) Delayed
Description: Groups randomized to DSMP Delayed will receive 6 weeks of DSMP classes after the 3 month post-test interview.~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization.
Study NCT02568293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBCV
Description: SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
Study NCT02568293 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is used as a control.
Study NCT04415034 — intervention group
Intervention type: OTHER
Intervention: VAS and 5-D itch pruritus assessment
Description: All subjects were evaluated for presence of pruritus using VAS and 5-D itch scale
Study NCT04568915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, DN
Study NCT04568915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maitland Mobilization
Description: TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, Maitland joint mobilization
Study NCT00379080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery
Study NCT00379080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tandutinib
Description: Given orally
Study NCT00379080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00379080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue samples
Description: Correlative studies
Study NCT01983696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% oxygen concentration
Description: the oocytes and embryos are cultured in the incubator with concentrations of 6% CO2,5%O2, and 89% N2
Study NCT00794248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine 5 mg
Description: Clarinex 5 mg daily x 7 days
Study NCT00794248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: Allegra 180 mg daily x 7 days
Study NCT01496950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10Hz active rTMS
Description: 10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
Study NCT01496950 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10Hz placebo rTMS delivered to the vertex
Study NCT02760823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid (Thioctacid)
Description: 600 mg/12 hours, IV (in the vein)
Study NCT02760823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Alpha Lipoic Acid)
Description: Normal saline in syringe simulating Alpha Lipoic Acid 600mg
Study NCT02302638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo culture in different single-step media
Description: Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
Study NCT01295671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of beverages
Description: Home delivery of specified beverage type
Study NCT01295671 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provision of beverages
Description: Home delivery of specified beverage type
Study NCT02674958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
Study NCT02492984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of Xyntha
Description: Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
Study NCT03313466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet cognitive behavioral therapy for insomnia (iCBTI)
Description: An internet-based program for providing individually tailored CBTI based on participant responses to questions and performance on weekly guided sleep strategies.
Study NCT03313466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Class in sleeping well and improving insomnia
Description: A group education session providing advice on healthy sleep habits and ways to improve common forms of insomnia.
Study NCT04128046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRFM injection
Description: Using a 27-gauge microcannula, a total of 4 mL of PRFM was injected intradermally into the mid-cheek and NLF (2 mL for each site) on one side of the face.
Study NCT04128046 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Using a 27-gauge microcannula, a total of 4 mL of saline was injected intradermally into the mid-cheek and NLF (2 mL for each site) on the contralateral side of the face.
Study NCT03685019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 degree flexion radiograph
Description: 20 degree flexion radiograph
Study NCT03685019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 45 degree flexion radiograph
Description: 45 degree flexion radiograph
Study NCT00530400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: preoperative intravenous 1.5g cefuroxime
Study NCT00530400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: preoperative intravenous placebo
Study NCT03493048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab, iv, 500mg/m2
Study NCT03546582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 targeted immunotherapy
Study NCT03546582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: High-precision radiotherapy
Study NCT03546582 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: High-precision radiotherapy
Study NCT00682721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo two pills once daily
Study NCT03493048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-FU 2400 mg/m² cont. inf.
Study NCT03493048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU 2400 mg/m² cont. inf.
Study NCT03493048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m²
Study NCT03493048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m²
Study NCT03493048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: leucovorin 200 mg/m²
Study NCT00682721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 1 gram daily x number of days active in the study
Study NCT02558933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate
Description: Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
Study NCT03493048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: leucovorin 200 mg/m²
Study NCT01652144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT7519M
Study NCT00809887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micafungin lock therapy
Study NCT00208390 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Summit Tapered Hip System
Description: A cementless, tapered femoral component for use in total hip replacement
Study NCT01851161 — intervention group
Intervention type: PROCEDURE
Intervention: computed tomography
Description: Undergo conventional CT scan in both supine and prone positioning
Study NCT01851161 — intervention group
Intervention type: PROCEDURE
Intervention: 4-dimensional computed tomography
Description: Undergo 4D CT scan in both supine and prone positioning
Study NCT00809887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin lock therapy
Study NCT01851161 — intervention group
Intervention type: RADIATION
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT04530786 — intervention group
Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~* 2004-2005: A/Wyoming H3N2; B/Shanghai~* 2006-2007: A/New Caledonia H1N1~* 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia
Study NCT04841278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS/ERCP
Description: EUS with possible interventions, including liver biopsy and/or cholangiography, and possible ERCP. No new experimental procedures are proposed, only new protocol for diagnosis and treatment of liver graft dysfunction.
Study NCT02509000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air purifier
Description: filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
Study NCT02509000 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: air purifier
Description: filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
Study NCT04198805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E [(all-rac)-α-tocopheryl acetate]
Description: Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months
Study NCT03511352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequent sit-to-stands
Description: Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
Study NCT04198805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid (DHA EE)
Description: DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months)
Study NCT04523571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT01204684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor lysate-pulsed DC vaccination
Study NCT01204684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor lysate-pulsed DC vaccination+0.2% resiquimod
Study NCT01204684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
Study NCT04292912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745
Description: GSK2798745 will be administered.
Study NCT04198805 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]
Description: DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months
Study NCT04198805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching soybean placebo (3 capsules) of all arms daily for 6 months.
Study NCT03742700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Description: T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
Study NCT03742700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Description: E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
Study NCT03742700 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Simulation of the use of e-cigarette
Description: The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
Study NCT00859079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
Study NCT00859079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human regular insulin intravenously
Description: Human regular insulin intravenously according to the Munich-registry.
Study NCT00683644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc taken once daily
Study NCT00683644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsules taken once daily